Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

16 results about "Hormone Receptor Modulators" patented technology

TETRAHYDROPYRIDO[3,4-B]INDOLS ESTROGEN RECEPTOR MODULATORS AND THEIR USES

ActiveMX431559BDiseaseHormone Receptor Modulators
Tetrahydropyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulating activity or function are described, having the structure of Formula I (see Formula), and pharmaceutically acceptable stereoisomers, tautomers, or salts thereof, with the substituents and structural features described herein. Pharmaceutical compositions and medicinal products comprising the compounds of Formula I are also described, as well as methods of using such estrogen receptor modulators, alone or in combination with other therapeutic agents, to treat diseases or pathological conditions that are mediated by or dependent on estrogen receptors.
Owner:F HOFFMANN LA ROCHE & CO AG

Androgen receptor modulators and uses thereof

PendingCN120813571AOrganic active ingredientsOrganic chemistryDiseaseHormone Receptor Modulators
Relates to androgen receptor modulators and uses thereof. The present invention relates to compounds of formula (I)-(VI), in particular to compounds of formula (I)-(VI), pharmaceutical compositions comprising these compounds and the use of these compounds for the prophylaxis or treatment of diseases, in particular for modulating androgen receptor activity and treating diseases including prostate cancer.
Owner:SHANGHAI HAIHE PHARMACEUTICAL CO LTD

Hormone receptor modulators for the treatment of metabolic conditions and disorders

ActiveCN116854681BGroup 5/15 element organic compoundsHormone Receptor ModulatorsAutoimmune condition
This invention relates to an activator of FXR, which can be used to treat autoimmune diseases, liver diseases, intestinal diseases, kidney diseases, cancer, and other diseases in which FXR plays a role, and has the formula (I): wherein L1, A, X1, X2, R 1 R 2 and R 3 As described in this article.
Owner:ARDELYX INC

Crystal form of thyroid hormone beta receptor modulator

PendingCN120208929AMetabolism disorderDigestive systemDiseaseHormone Receptor Modulators
The invention relates to a polymorphic form of a compound capable of serving as a thyroid hormone beta receptor modulator, a preparation method and application of the polymorphic form and a pharmaceutical composition containing the polymorphic form. The polymorphic form is applied to preparation of drugs for treating various thyroid-related diseases.
Owner:CHENGDU KANGHONG PHARMACEUTICAL GROUP CO LTD

Combinations of g-protein coupled hormone receptor modulators and melanocortin 4 receptor agonists and related methods of use

PCT designated stageWO2026096815A1Metabolism disorderCyclic peptide ingredientsDiseaseHormone Receptor Modulators
The present disclosure relates to methods of treating a disease or disorder comprising administering a combination of an MC4R agonist with a GCHR modulator.
Owner:RHYTHM PHARMACEUTICALS INC +4

Hormone receptor modulators

PCT designated stage expiredWO2025117536A1Organic active ingredientsOrganic chemistryHormone Receptor ModulatorsAndrogen Receptor Gene
The present disclosure provides compounds and methods for treating cancer, such as prostate cancer responsive to inhibition and / or degradation of androgen receptor ("AR") polypeptide, and / or breast cancer responsive to inhibition and / or degradation of estrogen receptor ("ER") polypeptide and / or AR polypeptide.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION

Estrogen receptor modulators and uses thereof

PendingCN120118067AOrganic active ingredientsMetabolism disorderDiseaseHormone Receptor Modulators
The invention belongs to the technical field of medicines, and relates to an estrogen receptor modulator and application thereof, in particular to a compound shown as a general formula (i), an isomer or pharmaceutically acceptable salt thereof and application thereof. The invention also relates to the use thereof as an estrogen receptor degradation agent, in particular as an estrogen receptor degradation agent, in the preparation of medicaments for treating and / or preventing estrogen receptor mediated or dependent diseases or disorders, and in the preparation of medicaments for treating and / or preventing diseases or disorders by degrading target proteins.
Owner:JIANGSU VCARE PHARMATECH

Local delivery of growth and repair promoting compounds for treating, reducing and / or preventing stress urinary incontinence and fecal incontinence

PendingUS20240424001A1Organic active ingredientsPeptide/protein ingredientsHormone Receptor ModulatorsFecal incontinence
The present invention relates to compositions and local delivery methods to increase pelvic tissue integrity and the treatment, reduction and / or prevention of stress urinary incontinence [SUI] and fecal incontinence [FI] due to weakness in pelvic floor. The treatment comprises of growth and / or repair promoting compound(s) [GRPCs] including but not limited to androgens, androgen receptor modulators, ghrelin, a ghrelin analog, an estrogen, an estrogen receptor modulator, or a combination thereof for delivery into the vagina, anorectal canal or through the mucosa in these viscera to treat pelvic floor disorders.
Owner:STATERA PHARMA INC

Octahydro fused azadecalin glucocorticoid receptor modulators

InactiveJP2024170470AOrganic active ingredientsSenses disorderHormone Receptor ModulatorsPharmaceutical drug
To provide new compositions and new methods for modulating GR receptors.SOLUTION: The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. In some embodiments, the present invention provides a pharmaceutical composition including a compound of the present invention and a pharmaceutically acceptable excipient. In some embodiments, the present invention provides a method of modulating a glucocorticoid receptor, the method including contacting a glucocorticoid receptor with a compound of the present invention, thereby modulating the glucocorticoid receptor.SELECTED DRAWING: Figure 1
Owner:CORCEPT THERAPEUTICS INC

Combinations of g-protein coupled hormone receptor modulators and melanocortin 4 receptor agonists and related methods of use

PCT designated stageWO2026096813A2Organic active ingredientsPeptide/protein ingredientsDiseaseHormone Receptor Modulators
The present disclosure relates to methods of treating a disease or disorder comprising administering a combination of GLP1R agonists and MC4R agonists.
Owner:RHYTHM PHARMACEUTICALS INC +4

Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator

PendingUS20250009721A1Organic active ingredientsDigestive systemHormone Receptor ModulatorsGlucose control
Methods and compositions are disclosed for diagnosing a patient suspected of suffering from, and for treating a patient suffering from, a disorder such as hypercortisolemia, metabolic syndrome, pre-diabetes, diabetes, Cushing's syndrome, Cushing's Disease, hyperglycemia secondary to hypercortisolemia, a liver disease, a cardiac disorder, high blood pressure, a blood clotting disorder, a cancer, a psychological disorder, weight gain, a disorder of glucose control, a bone disorder (e.g., osteoporosis), hypogonadism, pseudoacromegaly, pituitary tumors, functional hypercortisolism, ACTH secreting tumors, peripheral neuropathy, dyslipidemia and other disorders.The methods and compositions include administration of a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (GRM). The preferred heteroaryl-ketone fused azadecalin GRM is relacorilant ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone). In some cases, the GRM (e.g., relacorilant) is orally administered. In some cases, the GRM (e.g., relacorilant) is orally administered without food.
Owner:CORCEPT THERAPEUTICS INC

Preparation method of key intermediate of estrogen receptor regulator

PendingCN120887871AOrganic chemistryHormone Receptor ModulatorsAlkyl nitrites
The invention provides an amplified preparation method of a key intermediate of an estrogen receptor modulator, and belongs to the field of medical intermediates. The method comprises the following steps: by taking azetidine-3-one hydrochloride and 3-fluoro-1-halogenated propane as raw materials, reacting in the presence of alkali to obtain an intermediate 1; then carrying out reductive amination reaction on the intermediate 2 and 5-amino-2-methylpyridine to obtain an intermediate 2; reacting with nitrous acid ester in the presence of alkali to obtain an intermediate 3; and finally, reacting in the presence of acid to obtain the 5-((1-(3-fluoropropyl) azetidine-3-yl) amino) pyridinealdehydes. The method is simple and reliable in process and easy for industrial production; the generation amount of an isomer is reduced, and the reaction yield is improved.
Owner:SHANGHAI ZAIQI BIO TECH

Crystal form of thyroid hormone β receptor modulator

PCT designated stage expiredWO2025140327A1Metabolism disorderDigestive systemDiseaseHormone Receptor Modulators
The present invention relates to a polymorph of a compound that can be used as a thyroid hormone β receptor modulator, a preparation method therefor and a use thereof, and a pharmaceutical composition containing the polymorph. The use is a use in the preparation of drugs for treating various thyroid-related diseases.
Owner:CHENGDU KANGHONG PHARMACEUTICAL GROUP CO LTD

Estrogen receptor antagonist dosage forms

PendingJP2026500166AOrganic active ingredientsOrganic chemistryHormone Receptor ModulatorsActivating mutation
The present disclosure provides compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 39, 38, 39 JPEG2026500166000038.jpg48165 or a pharmaceutically acceptable salt thereof. The unit dosage forms described herein are suitable for oral administration. There remains a need for anti-estrogen agents that can completely inhibit estrogen receptors, including those encoded by both wild-type and mutant forms (e.g., those containing activating mutations) of the genes encoding estrogen receptor alpha (ERα) and estrogen receptor 1 (ESR1). Selective estrogen receptor modulators (SERMs) or degraders (SERDs) are particularly useful or promising tools for such treatment.
Owner:OLEMA PHARMACEUTICALS INC